Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes

Clinica Chimica Acta

Volumn 412, Issue 23-24, 2011, Pages 2063-2069

  Howard, Rebecca ^a   Leathart, Julian B S ^b   French, David J ^a   Krishan, Elaina ^a   Kohnke, Hugo ^a   Wadelius, Mia ^c   Van Schie, Rianne ^d   Verhoef, Talitha ^d   Maitland van der Zee, Anke Hilse ^d   Daly, Ann K ^b   Barallon, Rita ^a  

^a LGC   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UPPSALA UNIVERSITY   (Sweden)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Acenocoumarol; CYP2C9; Phenprocoumon; Point of care genotyping; VKORC1; Warfarin

Indexed keywords

DNA;

ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYP2C9 GENE; DNA PURIFICATION; GENE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; MOLECULAR PROBE; NUCLEOTIDE SEQUENCE; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; VKORC1 GENE;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; DNA PRIMERS; GENOTYPE; HUMANS; MIXED FUNCTION OXYGENASES; POINT-OF-CARE SYSTEMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 80052935202     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.07.013     Document Type: Article

References (39)

1. Sconce E.A., Khan T.I., Wynne H.A., et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005, 106:2329-2333.
2. Bodin L., Verstuyft C., Tregouet D.A., et al. Cytochrome P4502C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005, 106:135-140.
3. Wadelius M., Chen L.Y., Lindh J.D., et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009, 113:784-792.
4. Wadelius M., Chen L.Y., Downes K., et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005, 5:262-270.
5. Gage B.F., Lesko L.J. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 2008, 25:45-51.
6. Caraco Y., Blotnick S., Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008, 83:460-470.
7. Anderson J.L., Horne B.D., Stevens S.M., et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007, 116:2563-2570.
8. Hillman M.A., Wilke R.A., Yale S.H., et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res 2005, 3:137-145.
9. Epstein R.S., Moyer T.P., Aubert R.E., et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010, 55:2804-2812.
10. Eckman M.H., Rosand J., Greenberg S.M., Gage B.F. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009, 150:73-83.
11. Lenzini P.A., Grice G.R., Milligan P.E., et al. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost 2008, 6:1655-1662.
12. Burmester J.K., Berg R.L., Yale S.H., et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet Med 2011, 13:509-518.
13. van Schie R.M., Wadelius M.I., Kamali F., et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009, 10:1687-1695.
14. Enstrom C., Osman A., Lindahl T.L. A genotyping method for VKORC1 1173C>T by Pyrosequencing technology. Scand J Clin Lab Invest 2008, 68:427-430.
15. King C.R., Porche-Sorbet R.M., Gage B.F., et al. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am J Clin Pathol 2008, 129:876-883.
16. Verstuyft C., Robert A., Morin S., et al. Genetic and environmental risk factors for oral anticoagulant overdose. Eur J Clin Pharmacol 2003, 58:739-745.
17. Hatch E., Sconce E.A., Daly A.K., Kamali F. A rapid genotyping method for the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene. J Thromb Haemost 2006, 4:1158-1159.
18. Lefferts J.A., Schwab M.C., Dandamudi U.B., Lee H.K., Lewis L.D., Tsongalis G.J. Warfarin genotyping using three different platforms. Am J Transl Res 2010, 2:441-446.
19. Babic N., Haverfield E.V., Burrus J.A., Lozada A., Das S., Yeo K.T. Comparison of performance of three commercial platforms for warfarin sensitivity genotyping. Clin Chim Acta 2009, 406:143-147.
20. Jonas D.E., McLeod H.L. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci 2009, 30:375-386.
21. Wang L., McLeod H.L., Weinshilboum R.M. Genomics and drug response. N Engl J Med 2011, 364:1144-1153.
22. French D.J., Archard C.L., Brown T., McDowell D.G. HyBeacon probes: a new tool for DNA sequence detection and allele discrimination. Mol Cell Probes 2001, 15:363-374.
23. French D.J., Archard C.L., Andersen M.T., McDowell D.G. Ultra-rapid DNA analysis using HyBeacon probes and direct PCR amplification from saliva. Mol Cell Probes 2002, 16:319-326.
24. French D.J., Jones D., McDowell D.G., Thomson J.A., Debenham P.G. Analysis of multiple single nucleotide polymorphisms closely positioned in the ovine PRNP gene using linear fluorescent probes and melting curve analysis. BMC Infect Dis 2007, 7:90.
25. French D.J., McDowell D.G., Debenham P., Gale N., Brown T. HyBeacon probes for rapid DNA sequence detection and allele discrimination. Methods Mol Biol 2008, 429:171-185.
26. Daly A.K., Steen V.M., Fairbrother K.S., Idle J.R. CYP2D6 multiallelism. Cytochrome 1996, P450(Pt B):199-210.
27. Ben Gaied N., Richardson J.A., Singleton D.G., Zhao Z., French D., Brown T. End-capped HyBeacon probes for the analysis of human genetic polymorphisms related to warfarin metabolism. Org Biomol Chem 2010, 8:2728-2734.
28. Caldwell M.D., Awad T., Johnson J.A., et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008, 111:4106-4112.
29. Takeuchi F., McGinnis R., Bourgeois S., et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009, 5:e1000433.
30. Zhang J.E., Jorgensen A.L., Alfirevic A., et al. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet Genomics 2009, 19:781-789.
31. Perini J.A., Struchiner C.J., Silva-Assuncao E., Suarez-Kurtz G. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin Pharmacol Ther 2010, 87:417-420.
32. Sagreiya H., Berube C., Wen A., et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics 2010, 20:407-413.
33. Perez-Andreu V., Roldan V., Anton A.I., et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 2009, 113:4977-4979.
34. King C.R., Deych E., Milligan P., et al. Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost 2010, 104:750-754.
35. Voora D., Koboldt D.C., King C.R., et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010, 87:445-451.
36. Blaisdell J., Jorge-Nebert L.F., Coulter S., et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004, 14:527-537.
37. King B.P., Khan T.I., Aithal G.P., Kamali F., Daly A.K. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 2004, 14:813-822.
38. Tai G., Farin F., Rieder M.J., et al. In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenet Genomics 2005, 15:475-481.
39. Richardson J.A., Gerowska M., Shelbourne M., French D., Brown T. Six-colour HyBeacon probes for multiplex genetic analysis. Chembiochem 2010, 11:2530-2533.